Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

The researchers found that when the anti-cancer antibody binds to P-cadherin ... be pinched off and sucked into the cell as a tiny bubble. The whole P-cadherin/antibody/drug complex is then sent to a ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...